When will Merck announce Q2 2026 results?

The exact date has not been set, but it is expected in late July or early August 2026.

What is Keytruda and why is it important for Merck?

Keytruda (pembrolizumab) is an immunotherapy cancer drug that accounts for a large portion of Merck's revenue. Its patent expiry in 2028 could significantly impact the company's earnings.

What are analysts' expectations for Merck's Q2 results?

Analysts expect revenue of around $16 billion and EPS of $1.30, but actual figures may vary.

How has Keytruda's performance affected MRK stock recently?

MRK shares have risen about 15% over the past year, supported by strong Keytruda sales and market optimism about Merck's pipeline.

Merck Q2 Earnings Preview: Keytruda Remains the Star

Markets await Merck's (MRK) Q2 2026 earnings, expecting Keytruda to continue driving performance. Investors focus on sales figures and management outlook as the drug's patent expiry in 2028 approaches.

Merck & Co. (MRK) is poised to report its second-quarter 2026 financial results, with expectations that its blockbuster drug Keytruda will once again lead the way. Investors are closely watching Keytruda sales and management's forward-looking statements, especially given the drug's patent cliff in 2028.

Key Financial Metrics

Metric	Q2 2026	Q2 2025	Change
Revenue	TBD	$15.8B	-
Net Income	TBD	$3.2B	-
EPS	TBD	$1.28	-
Note: Actual figures will be released with the official announcement.

Key Highlights from the Report

The report is expected to emphasize Keytruda's performance, which accounts for a significant portion of Merck's revenue. Management may also discuss strategies to mitigate the impact of patent expiry, such as pipeline development or acquisitions.

Guidance

Merck has not yet issued formal guidance, but analysts anticipate management will provide an overview of post-Keytruda growth plans.

Impact on the Stock

MRK shares are trading near their 52-week highs, supported by Keytruda's strong performance. Any decline in drug sales or cautious guidance could pressure the stock.

What This Means for Investors

Investors should closely monitor Keytruda sales, as any slowdown could affect valuation. Clarity on the post-patent strategy will be critical for market confidence.